0001048477 2026-08-06 2026-08-06 0001048477 1 2026-08-06 2026-08-06 0001048477 2 2026-08-06 2026-08-06 iso4217:USD pure shares S-8 S-8 EX-FILING FEES 0001048477 BIOMARIN PHARMACEUTICAL INC N/A false false S-8 BIOMARIN PHARMACEUTICAL INC Equity Common Stock true 7650000 59.86 457929000.00 0.0001381 63239.99 Equity Common Stock true 4355297 59.86 260708078.42 0.0001381 36003.79 718637078.42 99243.78 0.00 99243.78 Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of common stock ("Common Stock") of BioMarin Pharmaceutical Inc. (the "Registrant") that become issuable under the Registrant's 2017 Equity Incentive Plan, as Amended April 1, 2025 (the "2017 Plan"), by reason of any stock dividend, stock split, recapitalization or other similar transaction effected that increases the number of outstanding shares of Common Stock. Estimated in accordance with Rule 457(h) and Rule 457(c) under the Securities Act. The price per share and aggregate offering price are based upon the average of the high and low prices of the Registrant's Common Stock on July 31, 2026 as reported on the Nasdaq Global Select Market. Pursuant to Rule 416(a) under the Securities Act, this Registration Statement shall also cover any additional shares of Common Stock of the Registrant that become issuable under the Amicus Therapeutics, Inc. 2025 Equity Incentive Plan (the "Amicus Plan"), by reason of any stock dividend, stock split, recapitalization or other similar transaction effected that increases the number of outstanding shares of Common Stock. Estimated in accordance with Rule 457(h) and Rule 457(c) under the Securities Act. The price per share and aggregate offering price are based upon the average of the high and low prices of the Registrant's Common Stock on July 31, 2026 as reported on the Nasdaq Global Select Market. The Amicus Plan was assumed by the Registrant and, as modified in connection with such assumption, permits equity awards thereunder to the extent permissible under applicable law and the Nasdaq Listing Rules.